Dermatologists' Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the United Arab Emirates.
Fatima Albreiki, Ayman Ahmed Essa Al Naeem, Muna Mohamed Al Safi, Ahmed Ameen, Pervaz Ahmad Mohammad, Mostafa Zayed, Haytham Mohamed Ahmed, Diala Hamza, Zeina Azrak, Samantha K Kurosky, Gerardo A Encinas, Peter Anderson, Ashley S Cha-Silva, Shailja Vaghela, Juliana Machado Canosa
{"title":"Dermatologists' Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the United Arab Emirates.","authors":"Fatima Albreiki, Ayman Ahmed Essa Al Naeem, Muna Mohamed Al Safi, Ahmed Ameen, Pervaz Ahmad Mohammad, Mostafa Zayed, Haytham Mohamed Ahmed, Diala Hamza, Zeina Azrak, Samantha K Kurosky, Gerardo A Encinas, Peter Anderson, Ashley S Cha-Silva, Shailja Vaghela, Juliana Machado Canosa","doi":"10.1007/s13555-026-01874-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Alopecia areata (AA), an autoimmune disease, causes hair loss on the scalp, face, and body, with approximately 2% prevalence in the Middle East. AA is associated with significant impacts to patient quality of life (QoL). This study evaluated dermatologist perceptions and experiences treating AA in the United Arab Emirates (UAE) as new targeted treatments became available, as well as patient disease burden and unmet treatment needs.</p><p><strong>Methods: </strong>Data were from the Adelphi Real World AA Disease Specific Programme™ (September 2022-March 2023). Dermatologists rated statements on diagnosing and managing AA by agreeing or disagreeing and provided clinical and treatment information on one patient each with mild, moderate, and severe/very severe AA. Some of these patients completed questionnaires (Skindex-16, Hospital Anxiety and Depression Scale, and Work Productivity and Activity Impairment-AA [WPAI-AA]). Results stratification included by percent scalp hair loss (SHL).</p><p><strong>Results: </strong>Analyses included 53 dermatologists and 144 patients. Most dermatologists reported severe AA management was difficult because of lack of effective treatments. A median SHL of 61.0% was reported as typical of severe AA. The most frequently reported factor informing disease severity was impact of AA on QoL. Overall, 32.6% of patients had physician-assessed severe/very severe AA. Anxiety and depression rates were consistent across SHL categories. Patients with ≥ 21% SHL reported significantly higher impact of AA on QoL (mean Skindex-16 scores). Patients with ≥ 50% SHL reported higher presenteeism on the WPAI-AA. Almost all patients were currently receiving their first AA treatment; patients with ≥ 50% SHL received different treatments than those with < 50% SHL. Healthcare resource utilization and costs were lower among patients with < 50% SHL.</p><p><strong>Conclusions: </strong>In the UAE, impacts on patient QoL and the economic burden associated with AA are important factors to consider and may aid dermatologists in setting treatment goals and selecting therapies as newer targeted therapies emerge.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-026-01874-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Alopecia areata (AA), an autoimmune disease, causes hair loss on the scalp, face, and body, with approximately 2% prevalence in the Middle East. AA is associated with significant impacts to patient quality of life (QoL). This study evaluated dermatologist perceptions and experiences treating AA in the United Arab Emirates (UAE) as new targeted treatments became available, as well as patient disease burden and unmet treatment needs.
Methods: Data were from the Adelphi Real World AA Disease Specific Programme™ (September 2022-March 2023). Dermatologists rated statements on diagnosing and managing AA by agreeing or disagreeing and provided clinical and treatment information on one patient each with mild, moderate, and severe/very severe AA. Some of these patients completed questionnaires (Skindex-16, Hospital Anxiety and Depression Scale, and Work Productivity and Activity Impairment-AA [WPAI-AA]). Results stratification included by percent scalp hair loss (SHL).
Results: Analyses included 53 dermatologists and 144 patients. Most dermatologists reported severe AA management was difficult because of lack of effective treatments. A median SHL of 61.0% was reported as typical of severe AA. The most frequently reported factor informing disease severity was impact of AA on QoL. Overall, 32.6% of patients had physician-assessed severe/very severe AA. Anxiety and depression rates were consistent across SHL categories. Patients with ≥ 21% SHL reported significantly higher impact of AA on QoL (mean Skindex-16 scores). Patients with ≥ 50% SHL reported higher presenteeism on the WPAI-AA. Almost all patients were currently receiving their first AA treatment; patients with ≥ 50% SHL received different treatments than those with < 50% SHL. Healthcare resource utilization and costs were lower among patients with < 50% SHL.
Conclusions: In the UAE, impacts on patient QoL and the economic burden associated with AA are important factors to consider and may aid dermatologists in setting treatment goals and selecting therapies as newer targeted therapies emerge.
简介：斑秃（AA）是一种自身免疫性疾病，可导致头皮、面部和身体的脱发，在中东地区的患病率约为2%。AA对患者生活质量（QoL）有显著影响。随着新的靶向治疗方法的出现，本研究评估了阿拉伯联合酋长国（UAE）皮肤科医生治疗AA的看法和经验，以及患者的疾病负担和未满足的治疗需求。方法：数据来自Adelphi Real World AA疾病特异性计划™（2022年9月- 2023年3月）。皮肤科医生通过同意或不同意对AA的诊断和管理陈述进行评分，并为轻度、中度和严重/非常严重AA的每一位患者提供临床和治疗信息。部分患者完成问卷调查（皮肤指数-16，医院焦虑和抑郁量表，工作效率和活动障碍- aa [WPAI-AA]）。结果分层包括头皮脱发百分比（SHL）。结果：分析包括53名皮肤科医生和144名患者。大多数皮肤科医生报告，由于缺乏有效的治疗方法，严重的AA治疗是困难的。重度AA典型的SHL中位数为61.0%。最常报道的影响疾病严重程度的因素是AA对生活质量的影响。总体而言，32.6%的患者有医生评估的严重/极严重AA。焦虑和抑郁率在SHL类别中是一致的。SHL≥21%的患者报告AA对生活质量的影响显著更高（平均Skindex-16评分）。SHL≥50%的患者在WPAI-AA上的出勤率更高。几乎所有患者目前都在接受首次AA治疗；结论：在阿联酋，AA对患者生活质量的影响和经济负担是需要考虑的重要因素，随着新的靶向治疗方法的出现，这可能有助于皮肤科医生制定治疗目标和选择治疗方法。
期刊介绍：
Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
